Dr. Reddy’s Laboratories (NYSE: RDY)

This investigation is for anyone who acquired securities in Dr. Reddy’s Laboratories (NYSE: RDY) prior to July 22, 2026.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by failing to timely disclose to investors that the Company was having material difficulty safely manufacturing semaglutide.

On July 22, 2026, Dr. Reddy’s announced its first quarter fiscal 2027 earnings, reporting, among other things, earnings per share of only $0.06, due in part to the adverse impact of a ₹2.4 billion provision related to out-of-specification semaglutide batches. CEO Erez Israeli said “The quarter’s EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Dr. Reddy’s Laboratories (NYSE: RDY) prior to July 22, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.